Steven D. Strausbaugh

Learn More
Improvements in outcomes for patients who have cystic fibrosis (CF) have been striking in the last 30 years. Median survival now approaches the fifth decade of life. Advances in the understanding of the basic defect and the pathobiology of CF have led to new treatments, some of which have undoubtedly contributed to this success. Improved understanding of(More)
A multi-center, prospective, open-label study was conducted in primary immunodeficiency disease patients to determine the tolerability and pharmacokinetics of a 10% liquid IgG preparation administered subcutaneously. Forty-nine subjects (3–77 years old) were enrolled. Pharmacokinetic equivalence of subcutaneous treatment was achieved at a median dose of(More)
An investigational 10% liquid intravenous immunoglobulin (IVIG) was studied in 63 patients with primary immunodeficiency (PID) at 15 study sites. Patients were treated every 3 or 4 weeks with 254–1029 mg/kg/infusion of IVIG. Overall, Biotest-IVIG infusions were well tolerated. The proportion of infusions that were associated with adverse events during(More)
BACKGROUND Pancreatic enzyme replacement therapy (PERT) is critical for correction of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF). METHODS This was a randomized, placebo-controlled PERT withdrawal study evaluating the efficacy and safety of PANCREAZE® (pancrelipase) in CF patients with EPI. Participants (n=49) entered an(More)
Background. Pancreatic enzyme replacement therapy is the standard of care for treatment of malabsorption in patients with cystic fibrosis (CF) and exocrine pancreatic insufficiency (PI). Aim. To evaluate efficacy and safety of a new formulation of pancrelipase (Ultrase MT20) in patients with CF and PI. Coefficients of fat absorption (CFA%) and nitrogen(More)
OBJECTIVE To evaluate the safety and efficacy of a novel microbial lipase (NM-BL) in a liquid formulation for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) in a phase IIa proof-of-concept study. STUDY DESIGN We conducted a double-blind, randomized, placebo controlled crossover study in patients with cystic(More)
  • 1